Dayli Partners
Dayli Partners is a Seoul-based venture capital firm founded in 2014, managing 47 funds with ~600B KRW ($430M) in current AUM and 123 portfolio companies across Bio-Healthcare and Financials-Governance verticals, supported by its D'LABS accelerator and multiple Korean government GP mandates.
- Company typePrivate
- Founded2014
- HeadquartersSeoul, South Korea
- Headcount11–50
- GTM typeB2B
- OfferingServices
What Dayli Partners does
Dayli Partners is a Seoul-based venture capital firm founded in 2014 that invests across Bio-Healthcare and Financials-Governance (fintech) sectors. The firm is headquartered in Gangnam-gu at Teheran-ro 201, Ajou Building 15F, and operates under a dual co-CEO model led by Seung-Ho Lee and Sean Shin. As of October 2025, Dayli manages 47 funds with a cumulative AUM of 6,846 billion KRW (approximately $4.9B USD) and a current AUM of 600 billion KRW (approximately $430M USD). The portfolio spans 123 companies and is supported by the in-house D'LABS accelerator program.
Dayli generates revenue through traditional VC fund economics: management fees on committed and deployed capital across its 47 fund vintages, supplemented by carried interest on portfolio exits. A significant portion of the AUM base is sourced through Korean government mandates — including KVIC, TIPS, Scale-up TIPS, KGIC, and AgriFood — for which Dayli serves as a selected General Partner. These government LP relationships provide a stable, programmatic fee base that is competitively defensible. The firm also deploys proprietary and co-investment capital into direct equity positions across two defined verticals.
Recent activity (late 2025 / early 2026) demonstrates scaled participation in biotech financings, including BreezeBio's $60M Series B and Galux's $29M Series B, alongside continued fintech activity such as the $13.5M investment in INFORYOU. The combination of government mandate expansion, growing AUM, and disciplined vertical focus positions Dayli as a thesis-driven specialist manager rather than a generalist Korean VC.
Dayli Partners firmographics
Firmographics- Name
- Dayli Partners
- Legal name
- (주)데일리파트너스
- Website
- https://dayli.partners
- Company type
- Private
- Founded year
- 2014
- Operating status
- Operating
- Headcount range
- 11–50 employees
- Short description
- Dayli Partners is a Seoul-based venture capital firm founded in 2014, managing 47 funds with ~600B KRW ($430M) in current AUM and 123 portfolio companies across Bio-Healthcare and Financials-Governance verticals, supported by its D'LABS accelerator and multiple Korean government GP mandates.
- Ownership category
- akta.pro rank
Dayli Partners industry classification
Industry- Product category
- Venture Capital Investment Services
- NAICS
- Portfolio Management and Investment Advice (52394), Other Investment Pools and Funds (5259)
- SIC
- Investment Advice (6282)
- akta.pro primary industry
- Sector-Focused Venture Capital (Vertical Specialists) (FSANAAAD)
- akta.pro secondary industries
- Early-Stage Venture Capital (Series A/B) (FSANAAAB), Healthcare & Life Sciences Growth Equity (FSANACAB)
Keywords
Where Dayli Partners is headquartered
LocationHeadquarters
- HQ city
- Seoul
- HQ country
- South Korea
- HQ region
- Asia
Offices1 record
Markets served
Dayli Partners business model
Business model- GTM type
- B2B
- Offering type
- Services
- Cost components
- Personnel, Operations, Marketing or Sales, Technology or R&D, Others
Revenue model
- Management Fees: Dayli Partners earns management fees on committed capital from their 47 funds under management totaling 6,846 billion KRW in cumulative assets.
- Carried Interest: Performance-based carried interest from successful portfolio company exits and IPOs.
Go-to-market motion1 record
Distribution channels1 record
Marketing channels5 records
Dayli Partners product offering
Product offeringCore offering
Dayli Partners is a specialized venture capital and investment firm that deploys capital into early-stage to growth-stage startups in two verticals: Bio-Healthcare (new drugs, medical devices, diagnostics, AI-driven biotech, digital healthcare) and Financials-Governance (fintech, insurance, financial services). The firm manages 47 funds with 6,846 billion KRW in cumulative assets under management and operates the D'LABS bio-healthcare accelerator program. Typical initial investments range from 2-10 billion KRW per portfolio company, supplemented by follow-on funding, TIPS/Scale-up TIPS program recommendations, business diagnostics, consulting, mentoring, and networking support.
Product overview
Dayli Partners is a specialized investment group operating in two primary sectors: Bio·Healthcare and Financials-Governance. The firm offers investment management services through multiple fund programs and operates D'LABS, a bio/healthcare-specific accelerator program. The Bio-Healthcare investment vertical covers new drugs, medical devices, diagnostics, AI-powered biotech, and digital healthcare companies. The Financials-Governance vertical focuses on fintech and financial services companies. The investment approach combines direct capital deployment, accelerator program support (D'LABS), TIPS program recommendations, and networking assistance for portfolio companies.
Differentiator
Problem solved
Functional benefit
Products and services
- D'LABS Bio-Healthcare accelerator program that provides direct investment, TIPS/Scale-up TIPS recommendations, consulting and mentorship from bio expert reviewers, and networking support for growth-stage value enhancement and self-sustaining capability building for startups founded within 7 years and pre-founders in bio/healthcare sectors.
- Bio-Healthcare Investment Services Investment services focusing on bio-healthcare sectors including new drugs, medical devices, diagnostics, AI-powered biotech, and digital healthcare. The firm manages funds and provides capital to portfolio companies across various stages.
- Financials-Governance Investment Services Investment services focusing on financial and fintech sectors, including companies like SureTech, Innosure, and INFORYOU FINANCIAL SERVICES. The firm provides growth capital and operational support for portfolio companies.
Companies that use Dayli Partners
Customer profileSegments2 records
Ideal customer profiles2 records
Dayli Partners technology and API
TechnologyTechnology focussed No
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Dayli Partners partnerships and signals
Strategic signalPartnerships
Two partnerships are on record, tiered minor.
- Woongjin Bio Cluster (우정바이오)minorPartnership with Woongjin Bio Cluster for D'LABS 5th cohort, providing specialized research infrastructure support and incubation facilities for selected biotech startups.
- Seoul National University Shihung CampusminorPartnership with SNU Shihung Campus for D'LABS 6th cohort, offering co-located startup incubation space at the SNU Shihung Bio Startup Campus along with investment opportunities.
Scale indicators4 records
Recent moves10 records
Expansion highlights5 records
Dayli Partners competitors and assessment
Company assessmentDirect peers
- UTC Investment: Korean VC manager with significant bio/healthcare and deep-tech exposure. Comparable AUM scale and Korean institutional LP relationships; competes for similar KVIC and Scale-up GP mandates.
- Atinum Investment: Korean venture capital and growth equity firm investing across bio/healthcare, TMT, and consumer. Directly comparable in size, sector breadth, and stage focus; overlaps with Dayli in Korean early-to-growth biotech investing.
- Korea Investment Partners (KIP): One of Korea's largest venture capital and growth equity managers, with dedicated bio/healthcare and ICT funds. Comparable to Dayli in sector specialization, GP program participation (KVIC mandates), and Korean institutional LP base.
- LB Investment: Korean venture and growth capital firm with active bio/healthcare and ICT deployment. Similar mid-market Korean VC profile, with overlapping co-investor networks and government GP program participation.
- Capstone Partners: Korean venture capital firm with bio/healthcare and technology focus. Comparable mid-market VC profile, with similar government GP program participation and Korean institutional co-investor base.
- KB Investment: Korean venture capital and private equity arm of KB Financial Group, with active bio/healthcare deployment. Comparable institutional sponsorship, GP program participation, and Korean LP ecosystem positioning.
- Mirae Asset Ventures: Venture and growth investment arm of Korea's Mirae Asset Financial Group. Directly comparable as a Korean institutional VC participating in bio/healthcare and growth rounds, and a co-investor alongside Dayli in portfolio companies such as Galux.
- InterVest: Korean venture capital and growth equity firm with active bio/healthcare and technology deal flow. Direct co-investor with Dayli Partners in Galux's $29M Series B, making it a natural peer in both sector focus and syndicate participation.
Others
- Korea Development Bank (KDB): Korean state-owned policy bank that co-invests directly in venture rounds alongside private VCs including Dayli (e.g., Galux Series B). Relevant as a capital ecosystem participant and indirect LP-counterparty rather than a direct VC competitor.
Broad incumbents
- IMM Investment: One of Korea's largest alternative investment managers, operating across private equity, venture, and credit. Larger and more diversified than Dayli, but overlaps meaningfully in Korean growth-stage bio/healthcare and fintech investing.
Market position
Strengths4 records
Weaknesses5 records
Competitive moat4 records
Key risks6 records
Key highlights6 records
Customer concentration
Dayli Partners social profiles
Digital presenceDayli Partners financial estimates
Financial estimateRevenue estimate
Valuation estimate
Dayli Partners leadership team
Management profileNumber of profiles
Profiles15 records
Dayli Partners funding detail
Funding detailFunding overview
Funding rounds
Investors
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Dayli Partners M&A and investment
M&A and investmentM&A
Investments114 records
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Dayli Partners
What does Dayli Partners do?
Dayli Partners is a specialized venture capital and investment firm that deploys capital into early-stage to growth-stage startups in two verticals: Bio-Healthcare (new drugs, medical devices, diagnostics, AI-driven biotech, digital healthcare) and Financials-Governance (fintech, insurance, financial services). The firm manages 47 funds with 6,846 billion KRW in cumulative assets under management and operates the D'LABS bio-healthcare accelerator program. Typical initial investments range from 2-10 billion KRW per portfolio company, supplemented by follow-on funding, TIPS/Scale-up TIPS program recommendations, business diagnostics, consulting, mentoring, and networking support.
Is Dayli Partners a public or private company?
Dayli Partners is a private company. It is classified as unknown and is currently operating.
When was Dayli Partners founded?
Dayli Partners was founded in 2014. It employs 11 to 50 people.
Where is Dayli Partners based?
Dayli Partners is headquartered in Seoul, South Korea, in the Asia region.
How does Dayli Partners make money?
Two revenue lines are on record. Management Fees are the primary driver. The others are carried Interest.
Who are Dayli Partners's main competitors?
Direct peers on record are UTC Investment, Atinum Investment, Korea Investment Partners (KIP), LB Investment, Capstone Partners, KB Investment, Mirae Asset Ventures and InterVest. Korea Development Bank (KDB) is listed as an others. IMM Investment is listed as a broad incumbent.
Does Dayli Partners have an API?
No public API is recorded for Dayli Partners.
What industry is Dayli Partners in?
Dayli Partners's product category is Venture Capital Investment Services. Its primary akta.pro industry code is FSANAAAD, Sector-Focused Venture Capital (Vertical Specialists), with a secondary code of FSANAAAB, Early-Stage Venture Capital (Series A/B). Its NAICS code is 52394 and its SIC code is 6282.